PMV Pharmaceuticals Reports Q2 GAAP EPS of -$0.41, Misses by $0.02

PMV Pharmaceuticals reported Q2 GAAP EPS of -$0.41, missing estimates by $0.02. The company had cash, cash equivalents, and marketable securities of $148.3 million as of June 30, 2025.

PMV Pharmaceuticals (NASDAQ: PMVP) has reported its second-quarter 2025 financial results, with a GAAP EPS of -$0.41, missing estimates by $0.02. The company ended the quarter with $148.3 million in cash, cash equivalents, and marketable securities as of June 30, 2025 [1][2].

The company's net cash used in operations for the six months ended June 30, 2025, was $36.5 million, compared to $17.8 million for the same period in 2024. The net loss for the quarter ended June 30, 2025, was $21.2 million, an increase from $1.2 million in the same period last year. The increase in net loss was primarily due to the sale of New Jersey accumulated net operating losses in the second quarter of 2024, with a corresponding $16.2 million income tax benefit [2].

Research and development (R&D) expenses for the quarter ended June 30, 2025, were $18.4 million, up from $14.6 million in the same period last year. General and administrative (G&A) expenses were $4.5 million, down from $5.5 million in the same period last year [2].

PMV Pharmaceuticals will host an investor webinar on Wednesday, September 10, 2025, at 8:00 AM ET to review interim analysis data from the Phase 2 PYNNACLE clinical trial. The interim analysis will include data for approximately 65 patients who have had at least 18 weeks of follow-up [2].

References:
[1] https://seekingalpha.com/news/4481519-pmv-pharmaceuticals-gaap-eps-of-0_41-misses-by-0_02
[2] https://www.globenewswire.com/news-release/2025/08/07/3129289/0/en/PMV-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Corporate-Highlights.html